Deciding whether to sell shares in a company—whether referring to Celestica under the ticker CLS or the Australian biotechnology giant CSL Limited—depends heavily on your personal financial goals, risk tolerance, time horizon, and original investment thesis. If your investment has achieved your target valuation, or if your portfolio has become overly concentrated in a single sector, taking profits or rebalancing your holdings can be a prudent strategy. Conversely, if the foundational business drivers, strong balance sheet, and long-term growth prospects of the company remain intact, holding the shares may align better with a patient, long-term wealth accumulation strategy. Market experts typically recommend reviewing recent quarterly earnings reports, evaluating current valuation multiples against historical averages, and assessing whether any negative fundamental changes have occurred within the business operations. Because personal financial situations, tax implications, and individual portfolio constraints vary greatly, it is crucial to avoid making emotional or reactive choices during periods of market volatility. Consulting a licensed financial advisor or independent investment professional who understands your complete financial picture will provide personalized guidance tailored specifically to your unique circumstances rather than relying on generalized market commentary.